We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01878942
Recruitment Status : Completed
First Posted : June 17, 2013
Last Update Posted : January 21, 2016
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
The purpose of this study is to characterize the acute psychological, physiological, endocrine, and pharmacokinetic, as well as long-term psychological effects of LSD in humans.

Condition or disease Intervention/treatment Phase
Healthy Drug: Placebo Drug: LSD Early Phase 1

Detailed Description:
Lysergic acid diethylamide (LSD) is the prototype hallucinogen used recreationally worldwide. In the 50-70s, LSD was also used to study psychotic-like states in normals ("model psychosis") and in "psycholytic psychotherapy". Potential research and therapeutic uses of LSD are now re-recognized and may include its use in brain research, treatment of cluster headache, and aid in psychotherapy and in terminally ill patients. A better and contemporary understanding of the pharmacology of LSD is important in the light of its widespread recreational, and potential scientific and therapeutic uses. The study has no primary therapeutic intentions but aims for a solid account of the clinical pharmacological characteristics of the drug. To characterize the acute physiological, psychological, endocrine, and pharmacological response to the administration of a single dose of LSD in healthy subjects the investigators use a randomized double-blind placebo-controlled cross-over design with two experimental sessions. Subjects will participate in a placebo and a LSD session. Subjective and cardiovascular responses will be repeatedly assessed throughout the experiments and plasma samples are collected for pharmacokinetics and endocrine measurements.Additionally long-term psychological changes associated with the LSD experience are assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study
Study Start Date : June 2013
Actual Primary Completion Date : February 2014
Actual Study Completion Date : December 2014

Arm Intervention/treatment
Placebo, LSD
Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
Drug: Placebo

Capsules containing mannitol looking identical to LSD

per os

Drug: LSD
200µg per os, single dose
Other Name: Lysergic acid diethylamide

Primary Outcome Measures :
  1. Subjective / psychological effects of LSD [ Time Frame: 24 hours ]
    repeated assessment of subjective effects with validated questionnaires

Secondary Outcome Measures :
  1. Physiological effects of LSD [ Time Frame: 24 hours ]
    Effect on blood pressure, heart rate, body temperature, and pupillary function

  2. Endocrine response of LSD [ Time Frame: 24 hours ]
  3. Pharmacokinetics of LSD [ Time Frame: 24 hours ]
    Time course of plasma concentration, half-life, pharmacokinetic-pharmacodynamic relationship

  4. Effect of LSD on prepulse inhibition [ Time Frame: 3 hours ]
    Pre-Pulse inhibition of the acoustic startle reflex

  5. Tolerability of LSD [ Time Frame: 24 hours ]
    Assessment of adverse effects

  6. Long-term psychological effects of LSD [ Time Frame: 12 months ]
    Assessment of long-term psychological effects after 1 and 12 months

  7. Genetic Polymorphisms [ Time Frame: assessed once, at time of screening visit or at time of end of study visit ]
    Effects of genetic polymorphisms on the response to LSD

  8. Effects on social cognition and empathy [ Time Frame: 8 h ]
    assessment of cognitive and emotional empathy, as well as of prosocial behaviour

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age between 25 and 65 years
  2. Understanding of the German language
  3. Understanding the procedures and the risks associated with the study
  4. Participants must be willing to adhere to the protocol and sign the consent form
  5. Participants must be willing to refrain from taking illicit psychoactive substances during the study
  6. Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session, as well as during the study day.
  7. Participants must be willing not to drive a traffic vehicle within 48 h following LSD administration.
  8. Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session.

Exclusion Criteria:

  1. Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (>150/95 mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder.
  2. Current or previous psychotic or major affective disorder
  3. Psychotic or major affective disorder in first-degree relatives
  4. Relevant prior illicit drug use (except tetrahydrocannabinol (THC)-containing products) more than 10 times or any time within the previous 2 months.
  5. Pregnant or nursing women.
  6. Participation in another clinical trial (currently or within the last 30 days)
  7. Use of medications that may interfere with the effects of the study medications (any psychiatric medications)
  8. Insufficient interpersonal relationship/rapport with study physician as judged by the study physician

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01878942

Layout table for location information
University Hospital Basel
Basel, Basel-Stadt, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Layout table for investigator information
Principal Investigator: Matthias E Liechti, MD, MAS University Hospital, Basel, Switzerland
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT01878942    
Other Study ID Numbers: EK 279/12
First Posted: June 17, 2013    Key Record Dates
Last Update Posted: January 21, 2016
Last Verified: January 2016
Keywords provided by University Hospital, Basel, Switzerland:
Mechanism of action
Prepulse inhibition
LSD-induced neuroendocrine effects
Long-term psychological effects
Additional relevant MeSH terms:
Layout table for MeSH terms
Lysergic Acid Diethylamide
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Receptor Agonists